INTRODUCTION
This brief overview presents three key points that play a major role in the economic evaluation of strategies based on antiviral drugs to prevent and control influenza. First, influenza-like illness (ILI) is usually defined as an acute febrile illness with symptoms of coughing, myalgia, headache or sore throat. However, influenza viruses are not the sole infectious agents responsible for ILI, and the proportion of ILI accounted for by influenza viruses varies greatly across the studies, i.e. from 15 to 70 . Second the burden of influenza in the % community depends on the virulence of the circulating strains and the characteristics of the population, either at-risk for medical complications or otherwise healthy. Third, annual flu vaccination is a consensual and recommended strategy among the at-risk population, and strategies based on antiviral drugs may not challenge those based on vaccination, at least in the at-risk population.
Influenza-positive rates in individuals suffering from ILI
A number of infectious agents can be responsible for ILI, including influenza viruses, adenoviruses, respiratory syncytial viruses, rhinoviruses, parainfluenza viruses, Mycoplasma pneumoniae and the Legionella spirella species.
There are various laboratory [1 ] diagnostic methods to identify influenza viruses.
The following diagnostic methods are here presented in decreasing order of time it [2 ] takes to see results: serology (2 weeks), viral isolation by culture (3 10 days), RT-PCR (Reverse Transcriptase Polymerase Chain suffering from ILI), the collection of specimens sent for identification and the method(s) used for diagnosis. This proportion will increase with testing of patients during flu epidemics, the use of a specific clinical case definition for ILI and sensitive diagnostic methods such as RT-PCR on good quality samples. When an influenza virus was identified by viral culture, the proportion of influenza-positive patients [2 ] younger than 65 years and seeking medical advice for ILI varied between 16 and 29 in surveillance data, but reached 40 in one
epidemiologic survey when a more specific clinical case definition of influenza was used. When the collection of specimens was [6 ] limited to unvaccinated patients and, above all, during flu epidemics, this proportion increased substantially, i.e. from 46 to 62 in % % clinical trials of neuraminidase inhibitors. When influenza virus was identified by viral culture plus another diagnostic method [7 -11 ] (serology or RT-PCR), an even higher proportion of influenza virus infections was found among patients in clinical trials of neuraminidase inhibitors (up to 71 and 77 , respectively).
%[9 ]
% [12 ] On the other hand, the proportion of patients with ILI seeking medical advice varies greatly across health care systems. The average population consulting with ILI over 10 winters (1987 96 ) was estimated at 0.85 in the UK, where the National Health Service -% recommends to avoid medical advice during flu epidemics.
It was estimated at 50 in a recent French National prospective survey, in [ 
] %
which it correlated strongly with the severity of symptoms, i.e. when patients could benefit the most from antiviral drugs. Assuming [14 ] Economic evaluations of neuraminidase inhibitors in adults that the proportion of influenza-positive infections is similar between patients currently seeking medical advice and those who are not, the burden of influenza is much greater than currently estimated, and it could be reduced significantly by extended strategies to prevent and control influenza.
Variability of the burden of influenza according to year and risk for medical complications

Virulence of circulating strains
The frequent antigenic changes (or antigenic drift) due to point mutations during viral replication may explain the occurrence of influenza epidemics each year and the possible recurrence of influenza infection in individuals. The virulence of the circulating strains is assessed by morbidity and mortality indicators, such as the total number of ILI or the peak-incidence of ILI as provided by surveillance systems ( ), and the excess of hospitalizations and deaths during influenza seasons. All influenza http://oms2.b3e.jussieu.fr/flunet/ [15 ] seasons were judged mild to moderate worldwide during the last decade, as compared to those that followed the first circulation of the H3N2 strain in 1968.
Distribution of the adult population according to risk for medical complications
The burden of influenza depends on the characteristics of the population regarding the risk of developing medical complications from influenza. In the at-risk population, influenza infection can lead to hospitalizations and deaths with significant effect on both health outcomes and medical costs (and intangible costs of premature death, if valued). In the otherwise healthy population, influenza infection remains a common infectious disease and the burden of influenza is then driven by indirect costs of lost work days and a consequent drop in productivity, as well as the direct costs of physician visits and antibiotic use. About 60 of the population of a developed country is % between 18 and 65 years of age, the vast majority of whom are otherwise healthy individuals. Accordingly, the otherwise healthy adults bear most of the economic burden of influenza.
The at-risk population includes, in most developed countries: individuals aged >65 years (i.e. individuals aged >70 years account for 90 of influenza-related deaths); residents of nursing homes and other chronic-care facilities that house individuals of any age who have % chronic medical conditions; adults and children who have chronic disorders of the pulmonary or cardiovascular system, including asthma; adults and children who have required regular medical follow-up or hospitalization during the preceding year because of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunosuppression.
The US Advisory Committee [16 ] on Immunization Practices recommended recently the annual vaccination of individuals aged 50 64 to increase the low vaccination rate -among individuals with high-risk conditions (a quarter of this age group), and encouraged the annual vaccination of children aged 6
[17 ] -23 months because they are at increased risk for influenza-related hospitalizations. [18 ] A consensual strategy: annual flu vaccination in the at-risk population
Annual flu vaccination in the at-risk population
A consensual strategy in developed countries is the annual flu vaccination of the at-risk population. A meta-analysis showed that influenza vaccination in individuals aged > 65 years reduced hospitalization risk by 50 and mortality risk by 68 . Moreover, annual % % [19 ] vaccination is a cost-saving strategy in the at-risk population where the costs are above all medical costs. , Annual vaccination has [20 21 ] enjoyed a steady growth in uptake in all developed countries and is viewed as a successful public health initiative. [22 ] None of the four antiviral drugs specific for influenza infection, i.e. amantadine, rimantadine, zanamivir, and oseltamivir, has been, as of yet, demonstrated to be effective in preventing serious influenza-related complications in the at-risk population (bacterial or viral pneumonia or exacerbation of chronic diseases or hospitalizations or deaths Accordingly chemoprophylaxis with antiviral drugs may be a relevant strategy in the unvaccinated at-risk population, either during flu epidemics or when a household contact is suffering from ILI. , However, chemoprophylaxis should remain a second best option [27 28 ] according to a recent economic study showing that vaccination was more cost-effective than chemoprophylaxis during flu epidemics in the elderly population. [29 ] Annual flu vaccination in the otherwise healthy population
In the otherwise healthy population, options to prevent and control influenza are directed towards the reduction of indirect costs of lost work days and consequent drops in productivity that account for most of the burden of influenza. The extension of annual flu vaccination to the otherwise healthy population and treatment by antiviral drugs are therefore competing strategies in this population. Economic evaluations of annual flu vaccinations of otherwise healthy adults have shown since 1995 that annual flu vaccination was a cost-saving strategy when performed at the workplace.
Difficulties in comparing the benefits of annual flu vaccination and antiviral drugs are [30 -34 ] discussed in the Expert opinion chapter (see below). Strategies to prevent and control influenza, including rapid diagnostic tests in the otherwise healthy population
The extension of annual flu vaccination to the otherwise healthy population and treatment by antiviral drugs represent two opposite strategies in terms of population involvement to maximize effectiveness. The effectiveness of annual vaccination is maximal when the vaccination coverage rate is 100 , whereas the effectiveness of antiviral drugs is maximal when antiviral drugs are selectively given to % patients with ILI, i.e. when the probability of influenza infection is at its highest. 
PHARMACOLOGY, EFFICACY, AND SAFETY OF NEURAMINIDASE INHIBITORS
Pharmacology of neuraminidase inhibitors
Orthomyxovirus influenza is a membrane-enveloped RNA virus containing surface-expressed proteins, i.e. hemagglutinin, neuraminidase (NA) and ion-channel M2 proteins. NA is a highly conserved protein with nearly the same amino-acid sequence and three-dimensional structure in influenza A and B strains. Neuraminidase inhibitors (NA-inhibitors) are rationally designed small molecules that bind tightly to NA and stop the influenza virus from spreading and infecting new cells, and thus slow the rate of infection. [35 ] As shown in there are two marketed NA-inhibitors, i.e. zanamivir (Relenza ) and oseltamivir (Tamiflu ), and peramivir is on Table 1 ® ® the board with expected marketing in 2003, if the ongoing randomized clinical trial confirms its promising laboratory features. For [36 -39 ] decades, two antiviral drugs inhibiting the ion-channel M2 proteins, i.e. amantadine and rimantadine, have been used to treat influenza infection. NA-inhibitors have several advantages over ion-channel M2 inhibitors: activity against influenza B viruses, absence of serious side effects, and lower rates of resistance development both in vitro and in vivo. , Moreover ion-channel M2 inhibitors are rarely [18 35 ] used in some developed countries, or even removed from the pharmacopoeia (e.g. rimantadine in France).
Efficacy and safety of neuraminidase inhibitors
According to a meta-analysis of clinical trials of zanamivir, 10 mg zanamivir inhaled twice daily reduced significantly, in intention-to-treat analysis, the median duration of flu symptoms by 1.38 days CI95 , 0.84 to 1.93 , the median time to become afebrile by
0.50 days CI95 , 0.23 to 0.77 , and the median time to return to normal activities by 0.90 days CI95 , 0.19 to 1. 61 . Similar results [40 ] were found in the clinical trials of 75 mg oseltamivir taken orally twice daily. , , [10 11 41 ] In the previous meta-analysis of clinical trials, 10 mg zanamivir inhaled twice daily showed no significant increase in side effects compared to a placebo.
However zanamivir is not recommended for treatment of patients with underlying airway disease due to the [40 ] risk of serious adverse effects, and because its efficacy has not been demonstrated in this population. With 75 mg oseltamivir taken [42 ] twice daily, nausea and vomiting were reported more frequently (nausea without vomiting, approximately 10 ; vomiting, approximately 9 % ) than among those individuals receiving a placebo (nausea without vomiting, approximately 6 ; vomiting, approximately 3 ). ,
] A limited number of adults enrolled in clinical trials of oseltamivir discontinued treatment because of adverse effects. [18 ] Zanamivir and oseltamivir have all been approved in 2002 in those developed countries that account for 85 of the world % pharmaceutical market, although this approval occurred at different times (see ). Several factors are likely to affect the choice of Table 1 NA-inhibitors in relation to patient compliance: the route of administration, the number of administrations per day, adverse effects and the price. To the extent that oseltamivir (Tamiflu ) leads the world market of NA-inhibitors despite its higher cost and increased adverse ® effects, we may guess that it is related to its oral route of administration, which is much more convenient than inhaled zanamivir. It [43 ] may also be linked to a more aggressive advertising campaign (e.g. Roche won the 2000 Australian Direct Marketing Association award, the first time a pharmaceutical company has walked away with this honor). If the current clinical trial confirms the efficacy of peramivir, peramivir taken orally once daily could challenge other NA-inhibitors.
One of the strong appeals of NA-inhibitors is their lower rates of resistance development as compared to ion-channel M2 inhibitors.
Drug resistance conferred due to changes in the NA active site could be monitored by NA inhibition assays. In vitro, NA substitutions 4 11 This review is limited to economic studies performed in otherwise healthy adults without taking into consideration the therapeutic options including ion-channel M2 inhibitors (see above). Our search procedure included all economic studies (with comparison of costs and benefits of at least two strategies to control influenza) published until October 2002 and selected on PUBMED by the following terms: neuraminidase inhibitor , zanamivir , oseltamivir , adult , cost-effectiveness analysis , cost-benefit analysis , and relevant " " " " " " " " " " " " [45 ] economic studies referenced in previous, selected papers.
ECONOMIC EVALUATIONS OF NEURAMINIDASE INHIBITORS TO CONTROL INFLUENZA IN OTHERWISE HEALTHY ADULTS
shows the 10 economic studies with evaluation of NA-inhibitors in adults. , , , Four studies looked for the In economic studies, NA-inhibitors result in 1) health benefits measured by days of flu symptoms avoided, Quality-Adjusted Life Years (QALYs) gained or intangible benefits measured by the willingness-to-pay for one day of flu symptoms averted; 2) reduction of medical costs by decreasing secondary infectious complications and related antibiotic use, and over-the-counter drugs (acetaminophen [53 ] and cough treatments) consumption; and 3) reduction in indirect costs. Productivity gains were all measured in the human capital [7 ] [ 54 ] approach with a lost work day averted valued at the median earnings for one day. [55 ] As shown in match of vaccine strains to the circulating influenza viruses. The influence of these latter parameters was consistently found in other economic evaluations of annual influenza vaccination of otherwise healthy adults. For instance, when the ILI attack rate decreased [30 -32 ] from 15 to 5 , individual net benefits provided by vaccination were divided by 8 (US 32 to 4), or it was no longer associated with % % $ [33 ] net benefits under a threshold of 6.3 .
% [34 ]
EXPERT OPINION
Incentives to pay for NA-inhibitors
The US Panel on Cost-Effectiveness in Health and Medicine and other leading health economists have recommended that economic evaluation should be performed from a societal perspective that incorporates all costs regardless of who incurs the costs. , However, [55 56 ] it seems justifiable to underline the different incentives to pay for NA-inhibitors from particular perspectives, i.e. the health-care payer, the firms, and the patients with ILI.
From the health-care payer perspective, NA-inhibitors may be an attractive option to the extent that they could reduce very costly influenza-related hospitalizations (e.g. pneumonia therapy was estimated at US 4,000 per week, or hospitalization at 222 per day),
but the probability of bearing the brunt of costly medical complications is very low and has a significant implication only in the at-risk 40 ] population. Interestingly, Burls et al. showed that a 6 reduction of high-risk patients hospitalized in a conservative sensitivity analysis % favoring NA-inhibitors decreased the cost-effectiveness ratio slightly, dropping from 54,000 to 48,000 per QALY.
From the firm s perspective, NA-inhibitors may be an attractive option to the extent that they reduce lost work days, and increase ' [54 ] the median time to return to normal activities. The measurement of productivity gains by the number of lost work days averted is a [40 ] conservative estimate, since it relies solely on the lack of physical presence and thus does not take into account the productivity losses that occur when a worker with ILI nonetheless comes to work. In our review, four economic studies took into account indirect costs [57 ] averted that generally favored NA-inhibitors. , However, indirect costs averted in two other economic studies represented a half [34 49 -51 ] to a third of the estimates of previous studies (see ) , either because all the adult population was taken into consideration (including Table 2 Economic evaluations of neuraminidase inhibitors in adults Expert Rev Pharmacoecon Outcomes Res . Author manuscript Page / 5 11 non-working adults), or because caregiving costs were used instead of earnings. Consequently, these two economic studies [47 ] [48 ]
showed that NA-inhibitors were not cost-effective.
With the perspective of patients with ILI, NA-inhibitors may be an attractive option to the extent that they could allow patients to return to normal activities earlier (of particular interest in liberal professions), they could prevent in-house secondary transmission of influenza infection (with further reduction in indirect costs), and they marginally reduce OTC consumption. Whereas the indirect costs incurred by some patients with ILI are substantial, no economic study has evaluated strategic options specifically dedicated to patients suffering from ILI.
An issue related to the perspective of economic analysis is the type of economic study performed to evaluate NA-inhibitors, either through a cost-effectiveness analysis or cost-benefit analysis. The usual decision rule for cost-effectiveness analysis consists of comparing the cost-effectiveness ratio to a given threshold, or the cost-effectiveness of other strategies, actually funded by the health-care payer. In our opinion, a cost-benefit analysis is more fitting for the problematic of NA-inhibitors in the otherwise healthy population given the health outcomes in this population (i.e., influenza-like illness is a short-term, non-fatal disease), the lack of payment or copayment for NA-inhibitors in most developed countries, and the willingness-to-pay of patients with ILI to reduce the length and severity of flu symptoms.
Uncertainty in modeling of economic studies reviewed
According to sensitivity analyses in economic studies of NA-inhibitors, the proportion of ILI due to influenza viruses and the measure of health benefits in terms of QALYs per day dramatically changed the cost-effectiveness of NA-inhibitors. The base case analysis of data taken during flu epidemics, respectively, and the number of QALYs was extrapolated from 0.284 and 0.364 QALYs per day based on generic multi-attribute utility instruments, respectively (see ). Table 2 Influenza-positive rates be considered as low estimates during flu epidemics. On the other hand, clinical trials were selective of their patient populations and in practice, influenza-positive rates should be considered as high estimates during flu epidemics. In our opinion, the effectiveness of NA-inhibitors would be best assessed by surveillance systems that are based on similar methods for diagnosis than those used in randomized clinical trials, although economic constraints could limit the use of a combination of two or more diagnostic methods.
Whatever the true influenza-positive rate fixed in base case analysis, a more specific clinical case definition of influenza did not " " really improve positive predictive value during flu epidemics. Cough and fever during the first 48 hours following disease onset were the best predictors of influenza infections in pooled results from randomized clinical trials of zanamivir, but their positive predictive value [58 ] of 79 should be compared to the influenza-positive rate of 66 in those trials, i.e. an absolute increase of positive predictive value of 13 
Measure of effectiveness by QALYs or a willingness-to-pay approach
Major health outcomes assessed in populations at high risk of influenza-related complications, , , are inapplicable to the [29 40 46 ] otherwise healthy population, since influenza did not cause a significant excess of deaths among healthy people < 65 years (0.02 per 10,000 individual-months (95 CI: 0.01 to 0.05)), nor a significant increase in the number of annual influenza-related % − [59 ] hospitalizations of those at low risk (i.e., maximum of 11 hospitalizations per 10,000 individuals).
In the cost-effectiveness analyses [59 ] reviewed, effectiveness was assessed by the number of flu days averted and often the recommended QALY approach. These two [56 ] measures are linked, since the health outcome depends on morbidity alone. In our opinion, the use of QALYs for short-term non-fatal diseases like ILI is problematic, since QALYs were constructed to assess the loss of quality of life in chronic diseases. The computation of QALYs gained by NA-inhibitors as a change in generic multi-attribute utility scores (i.e. EQ-5D, HUI3, QWB) with a secondary rescaling of QALYs gained over one year with previous instruments to one day for study purposes is not a validated method. Moreover, small [60 ] variations in QALYs at the denominator imply an implausibly huge variation of cost per QALY in sensitivity analysis. Finally, there is no consensus on the generic multi-attribute utility instrument to be used in economic evaluation of health interventions. The differences in instruments and sample surveyed explain the different utility weights shown in . Interested readers in that topic could refer to Table 2 Hawthorne and Richardson s review. ' [61 ]
The failures of these recommended methods to measure effectiveness of NA-inhibitors in otherwise healthy adults and previous considerations of the relevance of cost-benefit analysis for the evaluation of NA-inhibitors favor willingness-to-pay for a day of flu symptoms averted as a measure of health benefits. Two economic studies in our review involved median willingness-to-pay estimates [62 ] for one day of symptom relief, i. willingness-to-pay for flu vaccination was also recently tested. [63 ] The opportunity cost of antibiotic use in patients with ILI NA-inhibitors during flu epidemics prevented secondary infectious complications, and thus reduced antibiotic use and follow-up [53 ] visits in economic studies. However, this approach does not consider the unnecessary antibiotics prescribed to meet the expectations of patients with ILI, i.e. those given to about 50 of healthy patients visiting a physician in Europe, , and the US. Transforming these prescriptions for antibiotics to prescriptions for NA-inhibitors (rather than an overoptimistic crude decrease in antibiotics) should contribute to an overall decrease in antibiotic use --an important public health goal if we are to reduce the emergence and spread of antibiotic-resistant bacteria. , As recently stated, antibiotic treatment of adults with nonspecific upper respiratory tract infection is [66 67 ] not recommended. , Economic methods are currently lacking to account for the opportunity cost of unjustified antibiotic use with [68 69 ] possible emergence of resistance and future decrease in antibiotic effectiveness in justified indications.
, However, we believe that [70 71 ] the benefits associated with NA-inhibitors instead of unjustified antibiotic prescriptions should be substantial.
Acceptance of annual flu shots in the otherwise healthy population
Head-to-head comparisons of NA-inhibitors and annual vaccination showed that vaccination was a dominant option in both the at-risk adult population and the otherwise healthy population. , However, these two latter economic studies assumed that the annual [29 ] [34 48 ] vaccine acceptance rate would be 100 in the otherwise healthy population. Therefore, the costs of campaigns to promote and implement % flu vaccination were reduced to those related to the administration of vaccine. However, the vaccination coverage rate in the at-risk population, already targeted by flu vaccination for a decade, has shown that adults < 65 years are less likely to be vaccinated than those over 65 (e.g. 30 and 66 in 2000 in the US, respectively).
In a recent review, the perceived effectiveness of the vaccine and having % % [18 ] received the vaccine the previous year were consistent positive predictors of vaccine acceptance among healthy adults. On the other [72 ] hand, almost 60 of the 370 employees surveyed at a corporate workplace declined flu shots for the following reasons: perceived % likelihood of getting the flu is low (30 ) and perceived likelihood of reaction to the shot is high (38 ) . In our opinion, flu vaccination % % [72 ] campaigns are necessary to reach the level of coverage at which benefits from herd immunity could be achieved, e.g. the 60 goal in the % US at-risk population in 2000. Flu vaccination campaigns are surely associated with increasing marginal costs that should be added to [18 ] the vaccination strategy. As patient financial incentives like reductions in patient payment or copayment are significantly associated with the use of influenza vaccination, the question of who will pay for flu vaccination campaigns remains. [73 ] Additional economic studies are needed
As outlined in the previous chapter on the major uncertainty surrounding some of the model parameters, additional studies are needed to reduce the gap between knowledge and decision. Models should also be validated by observational economic studies designed to compare NA-inhibitors and vaccination strategies in the workplace and to account for year-to-year variations in ILI attack rates, ILI severity, and vaccine efficacy.
Whereas the costs incurred by patients with ILI are substantial, no economic study evaluated strategic options specifically dedicated to patients suffering from ILI, e.g. over-the-counter NA-inhibitors without physician visit, Rapid Flu Test and physician visit if the test is [74 ] positive (the test requires 15 to 20 minutes for completion and that is too long), and in-house prevention of influenza transmission. , [27 28 ] 
MARKET SIZE AND MARKET SHARE OF NA-INHIBITORS
Wall Street has essentially written off NA-inhibitors and anti-influenza drugs in general, due to poor sales of oseltamivir (Tamiflu ) [22 ] extended to prophylaxis in adults and adolescents (approval for Tamiflu in 2002), at-risk unvaccinated population (randomized ® controlled trials are on-going in the at-risk population or with patients with influenza-related hospitalizion, and e.g., the National Institute
For Clinical Excellence (NICE) in UK has reversed an earlier decision and now recommends the use of NA-inhibitors in the at-risk population following Burls et al. ) . Moreover, NA-inhibitors represent one of the first-line antiviral drugs in case of an influenza [40 ] pandemic. WHO has recommended national authorities and vaccine manufacturers to consider developing plans for ensuring the availability of antivirals ( ). Finally, a third NA-inhibitor, peramivir, should be http://www.who.int/emc/diseases/flu/whoguidelines.htm available in 2003. Peramivir is designed for once daily oral administration, making peramivir potentially more convenient for patients. A second generation NA-inhibitor is also in progress (developed by Biota & GlaxoSmithKline).
We believe that the point of view on NA-inhibitors will move from a vaccination challenger to a complementary option of vaccination.
The current point of view may be related to the situation in the at-risk population, in which annual flu vaccination is a consensual strategy, and NA-inhibitors were not seen favorably during their 1999 launch. Current developments showing the efficacy of NA-inhibitors as a complementary option of vaccination in the at-risk population, and the economic dominance of flu vaccination plus NA-inhibitors over flu vaccination alone or NA-inhibitors alone in the otherwise healthy population, should help us take a calmer view of NA inhibitors in times to come. [30 -34 ] KEY ISSUES Ten economic evaluations of neuraminidase inhibitors to control influenza in adults are reviewed. NA-inhibitors result in 1) health benefits measured by days of flu symptoms averted, QALYs gained or intangible benefits measured by the willingness-to-pay for a day of symptoms averted; 2) reduction of medical costs by decreasing secondary infectious complications and related antibiotic use; 3) productivity gains.
Flu vaccination dominated NA-inhibitors (3 studies), systematic treatment by NA-inhibitors of consulting patients with influenza-like illness dominated a selective drug prescribing strategy based on Rapid Flu Test results during flu epidemics (4 studies). With the heath-care payer perspective that includes only medical costs, NA-inhibitors were not cost-effective in otherwise healthy adults, but the cost-effectiveness ratio decreased substantially when all adults, including the at-risk population, were included (3 studies).
Choice of key parameter estimates were sensitive to the perspective of analysis with conservative estimates disfavoring NA-inhibitors from the health-care payer perspective, e.g., the proportion of influenza-like illness due to the influenza virus targeted by neuraminidase inhibitors varies from 34 to 70 .
% %
Cost-benefit analysis is advocated for the evaluation of NA-inhibitors in the otherwise healthy population due to difficulties in measuring QALYs gained, and because a willingness-to-pay approach, i.e. wtp for a day of symptoms averted, is more convenient.
The opportunity cost of unjustified antibiotic use in influenza-like illness is not valued.
A future reduction in neuraminidase inhibitor efficacy related to the development of neuraminidase inhibitor-resistant influenza viruses should be watched out for.
We recommend a cautious analysis of published economic evaluations of NA-inhibitors compared to annual influenza vaccine in the otherwise healthy population, given the fact that increasing marginal costs of vaccination are not taken into account.
Annual flu vaccination and NA-inhibitors should be seen as complementary options rather than competing ones.
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